Merit Medical(MMSI)2025-02-25 21:18Revenue Projections - Preliminary unaudited revenue for the year ended December 31, 2024, is projected to be approximately 1.357 billion, representing an increase of approximately 7.7% to 7.9% compared to 2023[2] - Preliminary constant currency revenue for the same period increased by approximately 8.4% to 8.6% year-over-year[5] - The impact of foreign exchange on preliminary unaudited revenue for 2024 is estimated at $7.9 million[9] - The preliminary unaudited revenue information is subject to completion of financial closing procedures and may materially differ from actual results[16] - The company does not typically disclose preliminary unaudited revenue due to the unpredictability of underlying assumptions[15] Financial Reporting - The financial results for Q4 and the full year 2024, along with fiscal year 2025 guidance, will be announced on February 25, 2025[3] - Merit Medical's management uses non-GAAP financial measures, such as constant currency revenue, to evaluate financial performance and compare results to prior periods[7] Company Operations - Merit Medical employs approximately 7,400 people worldwide and serves customers globally with a sales force and clinical support team of over 800 individuals[12] - The company is engaged in the development and distribution of proprietary medical devices used in various medical procedures, including cardiology and oncology[12] - Risks associated with the company's operations include supply chain disruptions, regulatory challenges, and potential product recalls[13]